Stocktip

Short Term Swine Flu Trades

Checkout:
www.investorideas.com/...

Relatively unknown Swine Flu Stock Play - BONU, Bioneutral Group, Inc.

Sector Close-Up, Biotech Stocks Swing with Swine Flu

POINT ROBERTS, Wash., Delta, B.C - April 27 2009 BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up on stocks moving on swine flu news and fears of a global pandemic. Companies providing potential solutions moved up as the market opened.

Biotech Stocks Sector Close-Up Trading April 27, 2009

BioCryst Pharmaceuticals Inc. (NasdaqGM: BCRX) trading up at$4.03, up $1.82 (82.35%) 10:31am ET
BioNeutral Group, Inc., (OTCBB: BONU) trading up at $0.24, up $ 0.08 (50.00%)
Generex Biotechnology Corporation (NasdaqCM: GNBT) trading at$ 0.57, gains of $0.23 (69.40%) 10:33am ET
Novavax Inc. (NasdaqGM: NVAX) trading at $3.18, up $1.76 (123.94%) 10:35am ET
Vical Incorporated (NasdaqGM: VICL) trading at$ 3.02, up $0.49 (19.37%) 10:24am ET
Company Snapshots:

BioCryst Pharmaceuticals Inc. (NasdaqGM: BCRX) BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma.

BioNeutral Group, Inc., (OTCBB: BONU) is a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

Novavax Inc. (NasdaqGM: NVAX) Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches.

PURE Bioscience (NASDAQ: PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Swine Flu Stocks Fizzle Out After Impressive Open

NVAX, BONU, BCRX, PURE
Checkout:
www.investorideas.com/...
Sector Close-Up, Biotech Stocks Swing with Swine Flu

POINT ROBERTS, Wash., Delta, B.C - April 27 2009 BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up on stocks moving on swine flu news and fears of a global pandemic. Companies providing potential solutions moved up as the market opened.

Biotech Stocks Sector Close-Up Trading April 27, 2009

BioCryst Pharmaceuticals Inc. (NasdaqGM: BCRX) trading up at$4.03, up $1.82 (82.35%) 10:31am ET
BioNeutral Group, Inc., (OTCBB: BONU) trading up at $0.24, up $ 0.08 (50.00%)
Generex Biotechnology Corporation (NasdaqCM: GNBT) trading at$ 0.57, gains of $0.23 (69.40%) 10:33am ET
Novavax Inc. (NasdaqGM: NVAX) trading at $3.18, up $1.76 (123.94%) 10:35am ET
Vical Incorporated (NasdaqGM: VICL) trading at$ 3.02, up $0.49 (19.37%) 10:24am ET
Company Snapshots:

BioCryst Pharmaceuticals Inc. (NasdaqGM: BCRX) BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma.

BioNeutral Group, Inc., (OTCBB: BONU) is a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

Novavax Inc. (NasdaqGM: NVAX) Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches.

PURE Bioscience (NASDAQ: PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.